Back to Search Start Over

RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease

Source :
Clinical Trials Week. November 24, 2008, 33
Publication Year :
2008

Abstract

Resverlogix Corp. ('Resverlogix') (TSX:RVX) announced that treatment with its lead drug RVX-208, a first in class ApoA-I/Prebeta-HDL elevating drug, in a post-hoc analysis from the Phase 1a clinical trial found [...]

Details

Language :
English
ISSN :
15436772
Database :
Gale General OneFile
Journal :
Clinical Trials Week
Publication Type :
News
Accession number :
edsgcl.190391642